Literature DB >> 5463535

Metabolism of 14C-labeled pyridostigmine in myasthenia gravis. Evidence for multiple metabolites.

P Kornfeld, A J Samuels, R L Wolf, K E Osserman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5463535     DOI： 10.1212/wnl.20.7.634

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

1.  A pharmacokinetic study of neostigmine in man using gas chromatography-mass spectrometry.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; J Hultman; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

2.  In vitro synthesis of metabolites of 14C-pyridostigmine.

Authors:  P A Burdfield; T N Calvey
Journal:  Experientia       Date:  1974-05-15

Review 3.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

4.  Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman; E Stålberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-10       Impact factor: 10.154

5.  The pharmacokinetics of pyridostigmine and 3-hydroxy-N-methylpyridinium in the rat: dose-dependent effects after portal vein administration.

Authors:  H E Barber; G R Bourne; T N Calvey; K T Muir
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

6.  Pharmacokinetics and oral bioavailability of pyridostigmine in man.

Authors:  S M Aquilonius; S A Eckernäs; P Hartvig; B Lindström; P O Osterman
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

7.  Orthogonal projection to latent structures and first derivative for manipulation of PLSR and SVR chemometric models' prediction: A case study.

Authors:  Fatma F Abdallah; Hany W Darwish; Ibrahim A Darwish; Ibrahim A Naguib
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.